Author name: Leonardo Arias

Powering the Next Wave of Cell Therapy: From iPSC-Derived Cells to In Vivo Reprogramming

As cell therapy advances toward clinical reality, iPSC-derived cellular products, in vivo reprogramming strategies, and manufacturing-ready reagent platforms are reshaping regenerative medicine and oncology. Recombinant antibodies and drug targets, e.g. endotoxin-free proteins, transmembrane proteins, and site-specifically labeled biomolecules are emerging as indispensable enablers of reproducibility, mechanistic insight, and clinical-scale success.

Powering the Next Wave of Cell Therapy: From iPSC-Derived Cells to In Vivo Reprogramming Read More »

9 Months In, FDA’s New Priority Voucher Program Still Clouded With Uncertainty

The FDA’s Commissioner’s National Priority Voucher program, unveiled in June 2025, is “shrouded in secrecy,” Democratic representative Jake Auchincloss said last month, as regulatory and biopharma leaders try to decode the criteria for investigational or approved drugs to receive a voucher.

9 Months In, FDA’s New Priority Voucher Program Still Clouded With Uncertainty Read More »

Scroll to Top